Imatinib Krka D.D.

Imatinib, the active ingredient in Imatinib Krka D.D., is a tyrosine kinase inhibitor presented as a tablet for oral use. It targets specific molecular pathways that drive certain cancers and is prescribed for adult patients with those diagnoses.

GNH USA supplies Imatinib Krka D.D. as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib is a tyrosine kinase inhibitor used primarily in hematologic malignancies and selected solid tumours driven by BCR‑ABL, c‑KIT or PDGFR signalling.

- Chronic Myeloid Leukemia (CML): reduces leukemic cell proliferation and induces remission. - Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): improves survival by targeting BCR‑ABL. - Gastrointestinal Stromal Tumour (GIST): inhibits c‑KIT driven tumour growth, leading to disease control.

Imatinib may cause a range of adverse reactions, from mild to severe, that require monitoring during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, especially of the ankles. - Muscle cramps: occasional painful muscle contractions. - Fatigue: general tiredness or lack of energy. - Diarrhoea: loose stools, often transient. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe neutropenia or thrombocytopenia: marked reduction in white blood cells or platelets. - Cardiac failure: signs of reduced cardiac output, such as dyspnoea. - Pulmonary hypertension: increased pressure in lung arteries. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: life‑threatening skin reactions.

Before initiating Imatinib, clinicians should assess baseline organ function and monitor patients regularly for emerging toxicities.

- Monitor liver function: obtain baseline and periodic LFTs. - Assess cardiac status: watch for signs of heart failure. - Check complete blood counts: monitor for neutropenia and thrombocytopenia. - Avoid use in patients with known hypersensitivity to imatinib or its excipients. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Imatinib interacts with several drugs that can alter its plasma concentration or increase toxicity risk.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise imatinib levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): lower imatinib efficacy. - Strong P‑glycoprotein inhibitors (e.g., verapamil): may increase systemic exposure.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): potential enhancement of anticoagulant effect. - Live attenuated vaccines: possible reduced vaccine efficacy. - Diuretics (e.g., furosemide): may exacerbate fluid retention and edema.